ABSTRACT
Surgery has been the cornerstone of curative therapy for patients with esophageal cancer. However, less than half of patients are suitable for potentially curative surgery, and even in patients who are physiologically fit and whose tumor appears resectable, two-thirds will relapse and die of locally recurrent and/or metastatic disease. Attempts have been made therefore to improve patient survival through the use of adjuvant therapy.
